For the quarter ending 2025-09-30, PLRX had $6,912K increase in cash & cash equivalents over the period. -$21,081K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -26,301 | -99,466 |
| Depreciation expense | 436 | 895 |
| Stock-based compensation expense | 6,418 | 15,291 |
| Gain on sale of property plant and equipment | 44 | - |
| Non-cash operating lease expense | 821 | 1,628 |
| Net amortization (accretion) on short-term investments and debt | -335 | -3,339 |
| Prepaid expenses and other current assets | -780 | -1,970 |
| Other non-current assets | 0 | -43 |
| Accounts payable | -897 | -4,580 |
| Accrued liabilities | -2,031 | -8,622 |
| Operating lease liabilities | -598 | 35 |
| Net cash used in operating activities | -21,081 | -89,467 |
| Purchase of short-term investments | 52,563 | 65,756 |
| Maturity of short-term investments | 80,328 | 170,731 |
| Purchase of property and equipment | 0 | 374 |
| Proceeds from sale of property, plant and equipment | 156 | - |
| Net cash provided by investing activities | 27,921 | 104,601 |
| Proceeds from issuances of common stock under benefit plans | 72 | 498 |
| Proceeds from term loan, net of issuance costs | 0 | 0 |
| Net cash provided by financing activities | 72 | 498 |
| Net increase in cash and cash equivalents | 6,912 | 15,632 |
| Cash and cash equivalents at beginning of period | 72,670 | - |
| Cash and cash equivalents at end of period | 95,214 | - |
PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)